|
1
|
Zhu Q, Jia L, Gao Z, Wang C, Jiang H, Zhang J, Dong L. A Tumor Environment Responsive Doxorubicin-Loaded Nanoparticle for Targeted Cancer Therapy. Mol Pharm 2014; 11:3269-78. [DOI: 10.1021/mp4007776] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Qian Zhu
- State
Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering
Research Center for microRNA Biology and Biotechnology, School of
Life Sciences, Nanjing University, Nanjing 210093, China
| | - Lixin Jia
- State
Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering
Research Center for microRNA Biology and Biotechnology, School of
Life Sciences, Nanjing University, Nanjing 210093, China
| | - Zhongfei Gao
- State
Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering
Research Center for microRNA Biology and Biotechnology, School of
Life Sciences, Nanjing University, Nanjing 210093, China
| | - Chunming Wang
- State
Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering
Research Center for microRNA Biology and Biotechnology, School of
Life Sciences, Nanjing University, Nanjing 210093, China
- State
Key Laboratory of Quality Research in Chinese Medicine, Institute
of Chinese Medical Sciences, University of Macau, Macau SAR, China
| | - Haoyang Jiang
- State
Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering
Research Center for microRNA Biology and Biotechnology, School of
Life Sciences, Nanjing University, Nanjing 210093, China
| | - Junfeng Zhang
- State
Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering
Research Center for microRNA Biology and Biotechnology, School of
Life Sciences, Nanjing University, Nanjing 210093, China
| | - Lei Dong
- State
Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering
Research Center for microRNA Biology and Biotechnology, School of
Life Sciences, Nanjing University, Nanjing 210093, China
| |
Collapse
|
|
2
|
Abstract
The application of antibodies as therapeutic agents in the treatment of cancer now represents a significant proportion of the oncology drug arena. Despite this success, the ability to engineer and exploit antibodies in many different formats is ensuring that new avenues for their therapeutic application are constantly being examined. This review examines a selection of novel antibody-based therapeutic strategies that are currently in late preclinical and clinical evaluation.
Collapse
|
|
3
|
Abstract
In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, in particular antibodies. Antibody–nanoparticle conjugates have the potential to elicit effective targeting and release of therapeutic targets at the disease site, while minimizing off-target side effects caused by dosing of normal tissues. This article provides an overview of various antibody-conjugated nanoparticle strategies, focusing on the rationale of cell-surface receptors targeted and their potential clinical application.
Collapse
Affiliation(s)
- Francois Fay
- School of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, BT9 7BL, UK
| | | |
Collapse
|
|
4
|
Literature alerts. J Microencapsul 1999; 16:665-79. [PMID: 10499845 DOI: 10.1080/026520499288843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|